ED Treatment denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for ed treatment are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Your ED Treatment as Duplicate Therapy

Aetna's duplicate-therapy denial indicates that Aetna's pharmacy benefit system identified an active or recent claim for another treatment in the same erectile dysfunction (ED) therapeutic category and flagged the new request as potentially redundant. This type of denial is generated programmatically and often reflects an administrative artifact — a prior fill that was never used, a prescription that was cancelled but not closed in the system, or a mid-year formulary or coverage transition — rather than a genuine situation where two identical treatments are being used concurrently.

## Why This Denial Is Appealable

Because duplicate-therapy denials are system-generated, they are particularly susceptible to appeal when you can provide pharmacy records showing there is no concurrent active use of the flagged treatment. Additionally, if your prescriber has a clinical reason to use a different agent within the ED treatment category — for example, a specific delivery mechanism, onset profile, or co-prescribing consideration that distinguishes the requested treatment from the prior one — that clinical rationale directly reframes the request as a distinct clinical choice rather than a duplicate. Aetna's own clinical policy typically requires evidence of actual concurrent use to sustain a duplicate-therapy denial.

## Federal Appeal Framework

Under ACA Section 2719, after exhausting Aetna's internal appeal process, you are entitled to independent external review by an accredited Independent Review Organization (IRO). ERISA Section 503 provides full-and-fair review rights with written reasoning at each stage for employer-sponsored plans. The window to file an external review request is approximately 4 months from the date of the final internal denial notice. Expedited review (72 hours) is available when your prescriber certifies that the standard timeline would seriously jeopardize your health.

## Concrete Appeal Steps and Timeline

1. Request the specific duplicate identified — ask Aetna in writing which treatment triggered the duplicate flag and the date of the last claim for that treatment. 2. Obtain a 12-month pharmacy claims history from your pharmacy or Aetna's member portal confirming no active duplicate fill. 3. File the internal appeal within the deadline on your Explanation of Benefits (EOB) — confirm Aetna's specific timeline, typically 180 days for ACA plans. 4. Submit prescriber documentation explaining the clinical distinction if relevant. 5. Request external review if Aetna upholds the denial after the internal process.

## Documentation to Gather

• Diagnosis confirmation: Chart notes with a clear ED diagnosis and relevant clinical context.
• Pharmacy claims history: A dated printout showing no concurrent active fill of the flagged duplicate treatment.
• Prescriber letter: A letter explaining the clinical basis for the requested treatment and confirming there is no concurrent duplicate use, or explaining the clinical distinction that makes this request appropriate even if both are in the same category.
• Criteria-mapping table: Obtain Aetna's published clinical policy for ED treatments, list each requirement in a table, and document the specific chart fact that satisfies each criterion. Attach this to your appeal package.